Brief: Abbott Receives FDA Approval For Its Tactiflex™ Duo Ablation Catheter To Treat People With Abnormal Heart Rhythms
08/09/2026 13:13
BRIEF-Abbott Receives FDA Approval For Its Tactiflex™ Duo Ablation Catheter To Treat People With Abnormal Heart Rhythms Sept 8 (Reuters) - Abbott Laboratories ABT.N:
ABBOTT RECEIVES FDA APPROVAL FOR ITS TACTIFLEX™ DUO ABLATION CATHETER TO TREAT PEOPLE WITH ABNORMAL HEART RHYTHMS
ABBOTT - TO BEGIN BROADER COMMERCIAL ADOPTION OF TACTIFLEX DUO IN U.S. IN COMING WEEKS
Source text: ID:nPn9mlf3qa
Further company coverage: ABT.N
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Abbott Laboratories
See all newsBrief: Abbott Announces Availability Of Panbio Covid-19/Flu A&B Self-Test In Canada
Perrigo to sell infant formula business to MeridianMade for up to $175 million
Brief: Abbott Initiates Pivotal Trial For Cephea™ Device, An Innovative Treatment For Mitral Heart Valve Disease
Corrected: German startup NVision shows new path to quantum computing chips in Nature paper
Brief: Abbott Receives FDA Approval For First Device To Treat Leaks After Heart Valve Replacement